sorafenib has been researched along with Anoxemia in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 13 (56.52) | 24.3611 |
| 2020's | 9 (39.13) | 2.80 |
| Authors | Studies |
|---|---|
| Du, FH; Li, YL; Li, ZD; Wu, J; Wu, LW; Zeng, LH; Zhang, C; Zhang, MM | 1 |
| Chen, Z; He, Q; Lin, N; Xie, Q; Yan, F; Yang, B; Ye, S; Yuan, T; Zhang, B; Zhu, H | 1 |
| Feng, T; Huang, X; Lai, C; Li, Y; Shang, J; Shi, Y; Yang, Q; Yao, Y; Zhang, Z; Zhong, D | 1 |
| Luo, J; Mu, X; Wang, Z; Yang, Q; Zhao, Y | 1 |
| Li, Y; Liu, M; Wang, Z; Zhao, Y; Zheng, Y | 1 |
| He, Z; Kong, Z; Li, S; Luo, C; Sun, J; Wang, Z; Ye, H; Zhang, S; Zheng, Y | 1 |
| Abdel-Reheim, MA; Aboregela, AM; Al-Ameer, AY; Alamri, MMS; Alfaifi, J; Cavalu, S; Hasan, AM; Hashish, AA; Khalid, TBA; Mohammed, OA; Saber, S; Saleh, LA; Senbel, A | 1 |
| Dai, Z; Deng, Y; Dong, L; Liang, L; Zan, Y | 1 |
| Gong, FL; Guo, XL; Li, YS; Wang, L; Yang, XX; Yu, LG; Zhang, XK; Zhao, L | 1 |
| Bao, MH; Wong, CC | 1 |
| Fang, C; Gao, P; Geng, P; Guo, L; Hu, C; Li, E; Liu, Y; Sun, M; Tang, L; Wang, C; Wang, J; Wang, Y; Xu, G; Yin, P; Yu, J; Zeng, J; Zhuang, Z | 1 |
| Fondevila, F; García-Palomo, A; González-Gallego, J; Mauriz, JL; Méndez-Blanco, C | 1 |
| Avritscher, R; Bankson, JA; Cortes, AC; Ensor, JE; Kingsley, CV; Maldonado, KL; Minhaj, AA; Mitchell, JM; Muñoz, NM; Polak, U; Rashid, A; Taghavi, H | 1 |
| Ewig, JM; Iyer, P; Mayer, JL | 1 |
| Waxman, DJ; Zhang, K | 1 |
| Luo, CL; Wu, XH; Zhao, CX | 1 |
| Fang, Q; Liu, S; Sun, J; Xu, H; Zhan, C; Zhang, S; Zhang, Y; Zhao, L | 1 |
| Bergheim, D; Branchi, V; Dietrich, D; Dietrich, J; Fischer, HP; Goltz, D; Kalff, JC; Kristiansen, G; Matthaei, H; Semaan, A | 1 |
| Cramer, T; Daskalow, K; Decker, G; Gonzalez-Carmona, MA; Hirt, S; Raskopf, E; Sauerbruch, T; Schmitz, V; Standop, J; Vogt, A | 1 |
| Chowdhury, NF; Kuge, Y; Murakami, M; Nishijima, K; Takiguchi, M; Tamaki, N; Yu, W; Zhao, S; Zhao, Y | 1 |
| Inagaki, Y; Ito, M; Kasai, C; Kusagawa, S; Nobori, T; Nojiri, K; Ogura, S; Shiraki, K; Sugimoto, K; Takei, Y; Tameda, M; Yamamoto, N; Yoneda, M | 1 |
| Fang, X; Jiang, H; Liang, Y; Liu, H; Liu, J; Liu, L; Meng, X; Song, R; Tian, L; Wang, J; Wang, L; Yin, D; Zheng, T | 1 |
| Adnane, J; Bortolon, E; Carter, CA; Chang, YS; Chen, C; Henderson, A; Ichetovkin, M; Levy, J; Lynch, M; McNabola, A; Taylor, IC; Trail, PA; Wilhelm, S; Wilkie, D; Xue, D | 1 |
2 review(s) available for sorafenib and Anoxemia
| Article | Year |
|---|---|
Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Cellular Reprogramming; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immune Checkpoint Inhibitors; Liver Neoplasms; Metabolic Networks and Pathways; Nivolumab; Protein Kinase Inhibitors; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Sorafenib; Tumor Microenvironment | 2021 |
Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Sorafenib; Tumor Microenvironment | 2018 |
21 other study(ies) available for sorafenib and Anoxemia
| Article | Year |
|---|---|
DYRK1A suppression attenuates HIF‑1α accumulation and enhances the anti‑liver cancer effects of regorafenib and sorafenib under hypoxic conditions.
Topics: Dyrk Kinases; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Phenylurea Compounds; Protective Factors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Sorafenib | 2022 |
CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Hypoxia; Liver Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides | 2022 |
ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Hypoxia; Liver Neoplasms; Sorafenib | 2023 |
Hypoxia-responsive nanocarriers for chemotherapy sensitization via dual-mode inhibition of hypoxia-inducible factor-1 alpha.
Topics: Antineoplastic Agents; Aspartic Acid; Caspase 3; Cell Hypoxia; Cell Line, Tumor; Cytochromes c; Dicumarol; Female; Glutathione; Humans; Hypoxia; Micelles; NAD; NADP; Nitroimidazoles; Oxygen; Phosphates; Polyethylene Glycols; Polymers; Quinones; Sorafenib; Thioredoxins | 2022 |
Coenzyme-depleting nanocarriers for enhanced redox cancer therapy under hypoxia.
Topics: Animals; Antioxidants; Cell Line, Tumor; Coenzymes; Glutathione; Humans; Hypoxia; Mice; NADP; Neoplasms; Nitroimidazoles; Oxidation-Reduction; Sorafenib | 2023 |
Self-adaptive nanoassembly enabling turn-on hypoxia illumination and periphery/center closed-loop tumor eradication.
Topics: Animals; Humans; Hypoxia; Lighting; Mice; Neoplasms; Sorafenib | 2023 |
Ganetespib (STA-9090) augments sorafenib efficacy via necroptosis induction in hepatocellular carcinoma: Implications from preclinical data for a novel therapeutic approach.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Hypoxia; Liver Neoplasms; Mice; Necroptosis; Sorafenib | 2023 |
Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Catechols; Cell Line, Tumor; Cell-Penetrating Peptides; Drug Resistance, Neoplasm; Glucosides; Hep G2 Cells; Humans; Hypoxia; Liver Neoplasms; Mice; Nanoparticles; Sorafenib; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
Galectin-3 expression and secretion by tumor-associated macrophages in hypoxia promotes breast cancer progression.
Topics: Adenocarcinoma; Animals; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Clodronic Acid; Coculture Techniques; Disease Progression; Female; Galectin 3; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Lymphatic Metastasis; Macrophages; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Pectins; Signal Transduction; Sorafenib | 2020 |
Global Metabolic Profiling Identifies a Pivotal Role of Proline and Hydroxyproline Metabolism in Supporting Hypoxic Response in Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Energy Metabolism; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Metabolome; Metabolomics; Phenotype; Proline; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma.
Topics: Animals; Biomarkers, Tumor; Capillary Permeability; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Disease Models, Animal; Hypoxia; Image Processing, Computer-Assisted; Liver Neoplasms; Magnetic Resonance Imaging; Male; Necrosis; Neovascularization, Pathologic; Permeability; Rats; Sorafenib | 2019 |
Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation.
Topics: Carcinoma; Carcinoma, Papillary; Child; Humans; Hypoxia; Iodine Radioisotopes; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Respiration, Artificial; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2014 |
Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Axitinib; Cell Line, Tumor; Disease Models, Animal; Humans; Hypoxia; Imidazoles; Indazoles; Male; Neoplastic Stem Cells; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cadherins; Cyclooxygenase 2; Drug Resistance, Neoplasm; Humans; Hypoxia; Kidney Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Snail Family Transcription Factors; Sorafenib; Transcription Factors; Tumor Cells, Cultured | 2015 |
MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Niacinamide; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemokine CXCL12; Chemotherapy, Adjuvant; Female; Hepatectomy; Humans; Hypoxia; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Sorafenib; Survival Analysis; Tissue Array Analysis; Young Adult | 2017 |
Combination of hypoxia and RNA-interference targeting VEGF induces apoptosis in hepatoma cells via autocrine mechanisms.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Feedback, Physiological; Hypoxia; MAP Kinase Kinase 4; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Receptors, Vascular Endothelial Growth Factor; RNA Interference; RNA, Small Interfering; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Humans; Hypoxia; Kidney Neoplasms; Mice; Mice, Nude; Misonidazole; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Radiopharmaceuticals; Sorafenib; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2012 |
Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Humans; Hypoxia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured | 2013 |
Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Niacinamide; Phenylurea Compounds; Piperidones; Sorafenib; Treatment Outcome; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays | 2013 |
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
Topics: Actins; Adenocarcinoma, Clear Cell; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Capillaries; Cell Line, Tumor; Female; Humans; Hypoxia; Immunohistochemistry; In Situ Nick-End Labeling; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Pyridines; Regional Blood Flow; Sorafenib; Vascular Endothelial Growth Factor A | 2007 |